Stay updated on Galegenimab in Geographic Atrophy AMD: Clinical Trial
Sign up to get notified when there's something new on the Galegenimab in Geographic Atrophy AMD: Clinical Trial page.

Latest updates to the Galegenimab in Geographic Atrophy AMD: Clinical Trial page
- Check6 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2. This appears to be a backend version update with no visible changes to study content or page layout.SummaryDifference0.0%

- Check14 days agoChange DetectedThe page shows Revision: v3.3.1, replacing the previous Revision: v3.2.0.SummaryDifference0.0%

- Check21 days agoChange DetectedDeleted the funding/operating status notice related to government funding. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check35 days agoChange DetectedResults have been posted for the GALLEGO study (Results First Posted 2024-03-27). The study status is Terminated due to an unfavorable benefit–risk balance.SummaryDifference0.3%

- Check64 days agoChange Detected- Updated operating-status notice and new version tag (v3.2.0) added; old version tag (v3.1.0) removed. The page now provides current status guidance and a newer software/document version.SummaryDifference3%

- Check71 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or update a v3.1.0.SummaryDifference0.1%

Stay in the know with updates to Galegenimab in Geographic Atrophy AMD: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Galegenimab in Geographic Atrophy AMD: Clinical Trial page.